Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials
Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties
SAN DIEGO, CA, USA I September 06, 2023 I Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has announced that Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered to Cidara its Election to Proceed Notice for CD388 (JNJ-0953) which is being developed for the universal prevention of influenza A and B. Responsibility for future development, manufacturing and commercialization activities of CD388 will be assumed by Janssen, which intends to transfer its rights and obligations under the agreement to another entity.
“The Election to Proceed notice represents an important accomplishment for CD388, the most advanced Cloudbreak ® DFC program,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The clinical and nonclinical data for CD388 support the potential for a single dose to provide universal protection from seasonal and pandemic influenza strains A and B. This milestone payment, in addition to potential future milestone payments, if achieved, will provide Cidara with additional non-dilutive capital that will be applied to advance our other Cloudbreak ® DFC programs.”
As part of its exclusive worldwide collaboration with Janssen, Cidara is studying CD388 in Phase 1 (NCT05285137 and NCT05619536) and 2a (NCT05523089) clinical trials evaluating safety and pharmacokinetics as well as efficacy as pre-exposure prophylaxis against an influenza virus in healthy volunteers during a human challenge study. Earlier this year, Cidara announced promising interim efficacy and safety data from the Phase 2a study. The interim analysis demonstrated that a single dose of CD388 decreased viral replication in the upper respiratory tract and lowered influenza incidence rate compared to placebo. As of the interim analysis, treatment with CD388 was generally well-tolerated, with no treatment emergent adverse events leading to study discontinuation or serious adverse events reported. Cidara continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a trials and will be reimbursed for all ongoing development activities by Janssen as provided in the Janssen Collaboration Agreement. The complete CD388 Phase 2a data package is currently anticipated to be delivered to Janssen later this year.
Cidara will receive a $7 million milestone payment from Janssen for the election to proceed for CD388 and other influenza DFCs. Under the collaboration agreement, Cidara is eligible to potentially receive an additional $685 million in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create “single molecule cocktails” comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing cancers and other serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. In addition, Cidara received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
SOURCE: Cidara Therapeutics
Post Views: 107
Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials
Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties
SAN DIEGO, CA, USA I September 06, 2023 I Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has announced that Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered to Cidara its Election to Proceed Notice for CD388 (JNJ-0953) which is being developed for the universal prevention of influenza A and B. Responsibility for future development, manufacturing and commercialization activities of CD388 will be assumed by Janssen, which intends to transfer its rights and obligations under the agreement to another entity.
“The Election to Proceed notice represents an important accomplishment for CD388, the most advanced Cloudbreak ® DFC program,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The clinical and nonclinical data for CD388 support the potential for a single dose to provide universal protection from seasonal and pandemic influenza strains A and B. This milestone payment, in addition to potential future milestone payments, if achieved, will provide Cidara with additional non-dilutive capital that will be applied to advance our other Cloudbreak ® DFC programs.”
As part of its exclusive worldwide collaboration with Janssen, Cidara is studying CD388 in Phase 1 (NCT05285137 and NCT05619536) and 2a (NCT05523089) clinical trials evaluating safety and pharmacokinetics as well as efficacy as pre-exposure prophylaxis against an influenza virus in healthy volunteers during a human challenge study. Earlier this year, Cidara announced promising interim efficacy and safety data from the Phase 2a study. The interim analysis demonstrated that a single dose of CD388 decreased viral replication in the upper respiratory tract and lowered influenza incidence rate compared to placebo. As of the interim analysis, treatment with CD388 was generally well-tolerated, with no treatment emergent adverse events leading to study discontinuation or serious adverse events reported. Cidara continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a trials and will be reimbursed for all ongoing development activities by Janssen as provided in the Janssen Collaboration Agreement. The complete CD388 Phase 2a data package is currently anticipated to be delivered to Janssen later this year.
Cidara will receive a $7 million milestone payment from Janssen for the election to proceed for CD388 and other influenza DFCs. Under the collaboration agreement, Cidara is eligible to potentially receive an additional $685 million in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create “single molecule cocktails” comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing cancers and other serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. In addition, Cidara received FDA approval for REZZAYO™ (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
SOURCE: Cidara Therapeutics
Post Views: 107
